Simple Summary Lung cancer treatment options vary depending on the type and stage of
the cancer. For non-small cell lung cancer (NSCLC), treatments may include surgery …

Many terpyridines and their metal complexes are known to exhibit remarkable potential for
the interaction of biological targets. Notably, a subtle change in the structure of the ligand …

Synergistic drug combinations can extend the use of poly (ADP-ribose) polymerase
inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de …

Ruthenium (II) complexes are attracting significant research attention as a promising class of
photosensitizers (PSs) in photodynamic therapy (PDT). Having previously reported the …

Organometallic compounds, including Ruthenium complexes, have been widely developed
as anti-cancer chemotherapeutics, but have also attracted much interest as potential anti …

This study focuses on the cytotoxic activity of ruthenium (II) complexes, denoted as Ru1–8,
which exhibit coordination with nitrogen (amine and amide), oxygen, and sulfur donor …

Triple negative breast cancer (TNBC) remains the breast cancer subtype with the poorest
prognosis and median survival rate. Targeting PARP1/2 with PARP inhibitors (PARPi) and …